BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--InNexus Biotechnology Inc. (TSX VENTURE: IXS) (OTCBB: IXSBF), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, today announced that Martin Weigert, Ph.D., Professor of Pathology/Director of the Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, has joined InNexus’ newly formed Scientific Advisory Board. He joins Dr. J. Donald Capra, President Emeritus of the Oklahoma Medical Research Foundation and InNexus SAB Chairman, Dr. Thomas Kindt, Dr. John D. Minna, Dr. Carlos L. Arteaga and Dr. Ellen Vitetta.
